https://pubmed.ncbi.nlm.nih.gov/31847614/
We have discussed the potential of antibiotic combinations to provide therapeutic synergy, rejuvenating the effectiveness of old antibiotics to which the bacteria had developed resistance previously. We have examined the current thinking and evidence on resistance reduction using combination therapies, with a review on toxicity and drug-drug

https://www.nature.com/articles/s41579-018-0141-x
These include the observations that antagonistic drug pairs can suppress resistance 40, that synergistic combinations can counterintuitively drive more rapid evolution of resistance than

https://www.nature.com/articles/ja2017102
When a complete two-drug interaction network was studied using 21 drugs, 42% of drug interactions were synergistic and 58% were antagonistic or suppressive (χ 2, P-value<0.001). 24 When a

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905495/
Because many drugs with theoretical basis have synergistic antibacterial effect in the experimental stage, drug combinations are expected to improve the increasingly severe bacterial drug resistance, thereby ensuring a bright future for AGAs. The combination of antibiotics and other drugs is an important strategy to overcome bacterial resistance.

https://www.nature.com/articles/s41598-018-25714-z
Antimicrobial resistance seriously threatened human health. Combination therapy is generally an effective strategy to fight resistance, while some data on its effects are conflicting. To explore

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496525/
Upon combination at an optimum synergistic ratio, two or more drugs can have a significantly enhanced therapeutic effect at lower concentrations. Hence, using drug combinations could be a new, simple, and effective alternative to solve the problem of antibiotic resistance and reduce susceptibility.

https://www.frontiersin.org/articles/10.3389/fcimb.2024.1369264/full
One avenue lies in developing new antimicrobial agents targeting novel mechanisms or exploiting weaknesses in resistance pathways. However, the pipeline for new antibiotics is slow and costly (Monserrat-Martinez et al., 2019). Therefore, combinatorial therapies using established and novel agents in strategic combinations are gaining traction (Muteeb et al., 2023). The key lies in synergism

https://www.sciencedirect.com/science/article/pii/S2405844024040155
In combination therapies, the interactions between antibiotics play an essential role in treating resistant antibiotics since they can present synergistic, additive, or antagonistic effects that, when determined, can propose treatment strategies that use a combination of more effective drugs [99, 100].

https://onlinelibrary.wiley.com/doi/10.1111/eva.13608
1 INTRODUCTION. Antibiotic resistance is a problem facing humanity on a global scale (Ahmad & Khan, 2019; Coates et al., 2020; Hernando-Amado et al., 2019; Maillard et al., 2020; Ventola, 2015).Not only is drug resistance to a single drug a threat to public health, but even more concerning, multidrug resistance in bacteria is reducing the number of viable treatment options.

https://www.sciencedirect.com/science/article/pii/S1369527420300710
We know that certain combinations are clinically or experimentally effective, and in silico we can even predict which antibiotics will be synergistic or antagonistic using modelling and pair-wise interaction networks [20, 21].Antibiotics target various parts of the cell (Figure 2 a), and several hypotheses have been raised surrounding how certain antibiotic combinations work together to be

https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2023.1293633/full
However, among all of these strategies, using "antibiotic adjuvants in combination with antibiotics" has proven to be the most successful and effective (González-Bello, 2017). Antibiotic adjuvants have emerged as a promising approach to counteract multi-drug resistance and restore the efficacy of existing antibiotics.

https://royalsocietypublishing.org/doi/10.1098/rsif.2012.0279
Medical and pharmacological communities have long searched for antimicrobial drugs that increase their effect when used in combination, an interaction known as synergism.These drug combinations, however, impose selective pressures in favour of multi-drug resistance and as a result, the benefit of synergy may be lost after only a few bacterial generations.

https://pubmed.ncbi.nlm.nih.gov/38143903/
Multidrug antibiotic resistance is an urgent public health concern. Multiple strategies have been suggested to alleviate this problem, including the use of antibiotic combinations and cyclic therapies. We examine how adaptation to (1) combinations of drugs affects resistance to individual drugs, and

https://www.nature.com/articles/s41586-018-0278-9
Screening pairwise combinations of antibiotics and other drugs against three bacterial pathogens reveals that antagonistic and synergistic drug-drug interactions are specific to microbial

https://journals.asm.org/doi/10.1128/spectrum.03726-22
Ceftobiprole is a late-generation β-lactam antibiotic developed for MRSA infections. Resistance has emerged to ceftobiprole, jeopardizing this agent's effectiveness. To identify synergistic agent combinations with ceftobiprole, an FDA-approved drug library was screened for potential synergistic combinations with ceftobiprole.

https://www.frontiersin.org/articles/10.3389/fcimb.2024.1369264/pdf
This synergistic antibiotic combination, ... Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr. Res. Pharmacol. Drug Discovery 3, 100110. doi: 10.1016/j.crphar.2022.100110 ... antibiotic resistance, synergistic treatment, antimicrobial nanocomposites, green synthesis, antimicrobial

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659931/
The selective advantage of resistant cells under synergistic drug combinations may lead resistant mutants to out-compete susceptible cells and accumulate further resistance mutations more quickly than under antagonistic or suppressive combinations. 45 While this suggests that using antagonistic or suppressive drug pairs can slow the rate at

https://pubmed.ncbi.nlm.nih.gov/33619062/
Tuberculosis (TB) is a leading global cause of mortality owing to an infectious agent, accounting for almost one-third of antimicrobial resistance (AMR) deaths annually. We aimed to identify synergistic anti-TB drug combinations with the capacity to restore therapeutic efficacy against drug-resistan

https://link.springer.com/protocol/10.1007/978-1-0716-3981-8_5
Antimicrobial resistance (AMR) has become a major public health issue [1,2,3,4].Traditional single-drug therapy (monotherapy) has contributed to the development of AMR alongside other issues such as overprescribing and lax stewardship policies [5,6,7,8,9].Combination therapy has emerged as a potential solution to address AMR [10,11,12].In this chapter, we will explore the current methodologies

https://www.frontiersin.org/research-topics/47998/synergistic-combinatorial-treatments-to-overcome-antibiotic-resistance
This special issue on Research Topic focuses, in addition to the currently practiced antimicrobial combination, on how various antimicrobial agents could act synergistically to overcome an antibiotic resistance mechanisms. This includes, but is not limited to, using novel antimicrobial molecules or bio-composites made biopolymers as adjuvants

https://www.youtube.com/watch?v=MwExuCWAcjM
Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmace

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594660/
One such approach is the use of drug combinations to effectively combat the MDR phenotype. Such efforts include antibiotic-antibiotic combinations, and the pairing of an antibiotic with a non-antibiotic adjuvant molecule to either directly target resistance mechanisms, such as the inhibition of β-lactamase enzymes, or to indirectly target resistance by interfering with bacterial signaling

https://asm.org/Articles/2018/September/Combination-Antibiotic-Testing-When-2-Drugs-are-Be
In reality, what these methods determine is not whether two drugs are better than one but whether 2 drugs, when used together, have an effect that is greater than the sum of their individual activities - whether, in other words, 2 drugs are better than 2. The checkerboard array. Antibiotic concentrations are expressed as multiples of the MIC.

https://pubmed.ncbi.nlm.nih.gov/28874848/
Abstract. Antibiotic effectiveness often changes when two or more such drugs are administered simultaneously and unearthing antibiotic combinations with enhanced efficacy (synergy) has been a longstanding clinical goal. However, antibiotic resistance, which undermines individual drugs, threatens such combined treatments.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10739078/
2.1. Creation and isolation of resistant mutants. Eight strains of resistant S. epidermidis (ATCC 14990) were independently evolved in a stepwise manner to each of six antibiotics (Table 1) and each of four focal three‐drug combinations known to be highly synergistic (Table 2).From here onward, individual antibiotics will be spelled out while combinations of antibiotics will be listed using